Okyo Pharma Limited ADR (OKYO) Stock Price, Quote & News

Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acu...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 20 7495 2379

Website: okyopharma.com

Address:

14/15 Conduit St, Floor 4, London, United Kingdom

M86Investments Jul. 24 at 6:31 PM

$OKYO added more 💪 future company 2027 🔥

0 · Reply

Orlandotrader Jul. 23 at 12:29 PM

$OKYO OKYO Pharma's Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company's ordinary shares on NASDAQ at $1.54 per share.

0 · Reply

MrTicker Jul. 22 at 2:00 PM

$OKYO OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director HUGIN 9:00 AM ET 7/22/2026

0 · Reply

Orlandotrader Jul. 22 at 12:40 PM

$OKYO OKYO Pharma's Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company's ordinary shares on NASDAQ at $1.40 per share. Insiders starting to Nibble.

0 · Reply

Orlandotrader Jul. 21 at 12:45 PM

$OKYO Chairman, Mr. Gabriele Cerrone has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital. Smart Money is Buying!!! Market is Delusional with this at 1.35.

0 · Reply

Orlandotrader Jul. 20 at 12:54 PM

$OKYO Keeren Shah, Chief Financial Officer of OKYO Pharma. "During the year we raised approximately $25 million, including the recent capital raise backed by renowned investment funds, which has strengthened our cash position The strengthened financial position, with cash and cash equivalents of approximately $20.6 million as of end of March 2026, provides OKYO with the resources to be fully funded through the completion of the recently FDA-agreed global Phase 3 pivotal trial

0 · Reply

Orlandotrader Jul. 18 at 5:12 PM

$OKYO This Equity will continue to be Abused until they announce Patient Recruitment. Think and Hope this starts in August.

0 · Reply

Orlandotrader Jul. 12 at 1:15 PM

$OKYO 14 Clinical Sites almost Ready to Start Taking on patients. 74 Corneal Pain Sufferers will not take long to find with 37 Placebo patients that can be instantly available. This Trial will move Quickly. First to market molecule with Highly experienced Management team with History of Bringing Big Ocular Drugs to the market place. Peak sales 350-500 Million. One Times sales puts this Asset at 500 Million Market cap. Price Target 7$ with Successful phase 3.

0 · Reply

Orlandotrader Jul. 8 at 6:24 PM

$OKYO Group Breakdown: 74 patients will receive the active drug (0.05% urcosimod) and 37 patients will receive the placebo.Timeline: OKYO Pharma intends to initiate enrollment later this year. Because it spans multiple sites across both the United States and Europe, recruitment is expected to move efficiently. Pivotal Phase 3 trials are strictly blinded to protect the scientific integrity of the data. Revealing interim results as patients participate can cause bias and invalidate the study in the eyes of regulatory agencies like the FDA. You will have to wait for the official topline results after all 111 patients complete their evaluation. Not Open label in Other words. We will have to wait till Trial outcome.

0 · Reply

OptionsArtist Jul. 8 at 5:56 PM

$OKYO It would be nice if we could run up a bit 🥹

10 · Reply

Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38

Jul 23, 2026, 12:00 PM EDT - 2 days ago

OKYO Pharma Announces Purchase of Shares by Director

2026-07-23T11:35:44.000Z - 2 days ago

Okyo Pharma CEO Robert Dempsey purchases 15,000 shares at $1.54

Jul 23, 2026, 7:00 AM EDT - 2 days ago

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

2026-07-22T16:05:13.000Z - 3 days ago

Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share

Jul 22, 2026, 12:00 PM EDT - 3 days ago

OKYO Pharma Announces Purchase of Shares by Chairman

2026-07-22T14:05:29.000Z - 3 days ago

Okyo Pharma says CDO Gary Jacob purchases 3,500 shares for $1.40 per share

Jul 22, 2026, 10:00 AM EDT - 3 days ago

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

2026-07-22T11:31:00.000Z - 3 days ago

Okyo Pharma CMO Flavio Mantelli purchases 20,000 shares at $1.40

Jul 22, 2026, 7:00 AM EDT - 3 days ago

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

Jul 21, 2026, 9:00 AM EDT - 4 days ago

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

2026-07-21T11:25:37.000Z - 4 days ago

Okyo Pharma chairman Gabriele Cerrone buys 25,000 shares at $1.40 per share

Jul 20, 2026, 7:00 AM EDT - 5 days ago

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

Jul 20, 2026, 7:00 AM EDT - 5 days ago

OKYO Pharma Annual report: Q4 2026

Jul 13, 2026, 9:00 AM EDT - 12 days ago

OKYO Pharma Slides: Investor presentation

2026-07-13T10:05:05.000Z - 12 days ago

Okyo Pharma price target lowered to $5 from $7 at H.C. Wainwright

2026-07-08T11:30:42.000Z - 17 days ago

Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway

Jul 8, 2026, 7:00 AM EDT - 17 days ago

OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain

Jul 7, 2026, 7:00 AM EDT - 18 days ago

OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium

May 19, 2026, 7:00 AM EDT - 2 months ago

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

Apr 29, 2026, 7:00 AM EDT - 3 months ago

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Apr 7, 2026, 7:00 AM EDT - 3 months ago

OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting

Mar 19, 2026, 12:00 PM EDT - 4 months ago

OKYO Pharma Announces Chairman and Founder Acquires Shares

2026-03-19T14:15:16.000Z - 4 months ago

Okyo Pharma director John Brancaccio acquires 5,000 shares

Mar 19, 2026, 10:00 AM EDT - 4 months ago

OKYO Pharma Announces Director Acquires Shares

2026-03-19T11:37:09.000Z - 4 months ago

Okyo Pharma CDO, director acquire shares

Mar 19, 2026, 7:00 AM EDT - 4 months ago

OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

2026-03-18T11:22:52.000Z - 4 months ago

Okyo Pharma reports results from Phase 2a trial of urcosimod

Mar 18, 2026, 7:00 AM EDT - 4 months ago

OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain

Feb 23, 2026, 11:00 AM EST - 5 months ago

OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

2026-02-20T10:12:28.000Z - 5 months ago

Okyo Pharma initiated with an Overweight at Piper Sandler

Feb 12, 2026, 10:20 PM EST - 5 months ago

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

2026-02-12T22:20:33.000Z - 5 months ago

Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90

2026-02-12T21:06:40.000Z - 5 months ago

Okyo Pharma announces ordinary shares offering, no amount given

Feb 12, 2026, 4:01 PM EST - 5 months ago

OKYO Pharma Announces Public Offering of Ordinary Shares

Feb 11, 2026, 10:09 AM EST - 5 months ago

OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

2026-02-10T13:16:08.000Z - 5 months ago

Okyo Pharma appoints Mantelli as Chief Medical Officer

Feb 10, 2026, 8:00 AM EST - 5 months ago

OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Feb 2, 2026, 7:00 AM EST - 6 months ago

OKYO Pharma Registration statement: Registration filing

Jan 30, 2026, 11:30 AM EST - 6 months ago

OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

2026-01-28T12:45:43.000Z - 6 months ago

Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod

Jan 28, 2026, 7:40 AM EST - 6 months ago

OKYO Pharma Announces Successful Type C Meeting with the FDA

2026-01-23T12:11:12.000Z - 6 months ago

Okyo announces FDA authorized single-patient expanded IND for urcosimod

Jan 23, 2026, 7:00 AM EST - 6 months ago

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

2026-01-05T12:21:22.000Z - 7 months ago

Okyo Pharma appoints Robery Dempsey as CEO

Dec 19, 2025, 7:00 AM EST - 7 months ago

OKYO Pharma to Ring the Opening Bell at Nasdaq

2025-12-15T13:35:29.000Z - 7 months ago

Okyo Pharma chairman acquires 24,551 company shares

2025-12-11T13:41:22.000Z - 8 months ago

Okyo Pharma’s urcosimod shows favorable corneal nerve outcomes in Phase 2 trial

Nov 18, 2025, 8:30 AM EST - 8 months ago

OKYO Pharma to Present at OIS XV in San Diego

Sep 22, 2025, 8:30 AM EDT - 10 months ago

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

Jul 18, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma Annual report: Q4 2025

Jul 16, 2025, 9:21 AM EDT - 1 year ago

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Jun 11, 2025, 10:05 AM EDT - 1 year ago

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

May 19, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Apr 30, 2025, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Mar 31, 2025, 8:00 AM EDT - 1 year ago

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

Jan 31, 2025, 7:00 AM EST - 1 year ago

OKYO Pharma Announces Chairman and CEO Acquire Shares

Jan 30, 2025, 9:45 AM EST - 1 year ago

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

Nov 15, 2024, 9:00 AM EST - 1 year ago

MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MUSQ

Oct 23, 2024, 7:00 AM EDT - 1 year ago

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

Aug 23, 2024, 9:00 AM EDT - 2 years ago

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SMXT

Aug 23, 2024, 9:00 AM EDT - 2 years ago

OKYO Pharma CEO Interview to Air on Bloomberg TV

Aug 23, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Chairman Acquires Shares

Aug 15, 2024, 12:13 PM EDT - 2 years ago

OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 13, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Annual report: Q4 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use

Jul 11, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101

Jul 10, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease

Apr 30, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

Apr 8, 2024, 7:00 PM EDT - 2 years ago

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$

Apr 2, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Mar 22, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Mar 21, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Mar 20, 2024, 7:00 AM EDT - 2 years ago

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

Feb 9, 2024, 7:00 AM EST - 2 years ago

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

M86Investments Jul. 24 at 6:31 PM

$OKYO added more 💪 future company 2027 🔥

0 · Reply

Orlandotrader Jul. 23 at 12:29 PM

$OKYO OKYO Pharma's Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company's ordinary shares on NASDAQ at $1.54 per share.

0 · Reply

MrTicker Jul. 22 at 2:00 PM

$OKYO OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director HUGIN 9:00 AM ET 7/22/2026

0 · Reply

Orlandotrader Jul. 22 at 12:40 PM

$OKYO OKYO Pharma's Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company's ordinary shares on NASDAQ at $1.40 per share. Insiders starting to Nibble.

0 · Reply

Orlandotrader Jul. 21 at 12:45 PM

0 · Reply

Orlandotrader Jul. 20 at 12:54 PM

0 · Reply

Orlandotrader Jul. 18 at 5:12 PM

$OKYO This Equity will continue to be Abused until they announce Patient Recruitment. Think and Hope this starts in August.

0 · Reply

Orlandotrader Jul. 12 at 1:15 PM

0 · Reply

Orlandotrader Jul. 8 at 6:24 PM

0 · Reply

OptionsArtist Jul. 8 at 5:56 PM

$OKYO It would be nice if we could run up a bit 🥹

10 · Reply

Oscarca Jul. 8 at 4:31 PM

$OKYO https://okyopharma.com/okyo-pharma-reports-positive-feedback-from-fda-type-d-meeting-and-accelerates-urcosimod-into-global-phase-3-pivotal-trial-for-neuropathic-corneal-pain/?fbclid=IwdGRjcAS7WktwZG9mA2ZkaWQWUKJg2aAiifPcRnTSXNNnJe4jvNuT0GV4dG4DYWVtAjExAHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR7oOx_OFb616QEPwcZUXl35uzZFJHvwqPPkmXRsaogY-_mLXXvOb5VBVomSNw_aem_GnjL-RCZQh0XL5vBfCgyxQ

1 · Reply

Orlandotrader Jul. 8 at 4:28 PM

$OKYO Ultimately, the previous meeting established the general groundwork for clinical progression, while today's Type D meeting validated a significantly de-risked, shortened, and more cost-effective commercial pathway to advance urcosimod. Wall Street analysts and independent research reports project peak annual sales for urcosimod to range from $328 million to $500 million+. The Multibillion-Dollar Unmet Need: Urcosimod is aiming to treat an addressable market worth multiple billions of dollars globally. Because there are currently no FDA-approved therapies specifically for Neuropathic Corneal Pain, the first drug to market will command significant pricing power and market share.

0 · Reply

Orlandotrader Jul. 8 at 4:23 PM

$OKYO The new FDA alignment provides distinct advantages that were not finalized in the earlier Type C meeting:Potential Single-Trial Registration: The FDA indicated that the NEPTUNE trial could serve as a single-trial registration pathway to market, meaning if the trial is successful, they may not need to conduct a second phase 3 trial before submitting a New Drug Application (NDA).Finalized Study Protocol: The study has been locked in to enroll approximately 111 subjects across the US and Europe with a 2:1 randomization of 0.05% urcosimod versus placebo.

1 · Reply

Orlandotrader Jul. 8 at 4:07 PM

$OKYO And Hence the Delay!!! Earlier this year (January 2026): OKYO announced alignment following a Type C meeting. At that time, the plan was to run a Phase 2b/3 trial with 120 subjects to clear a path forward, evaluate primary endpoints, and then hold an end-of-phase meeting to determine the next steps.Today (July 2026): OKYO announced positive feedback from a Type D meeting. They shifted their strategy to bypass the intermediate steps and move directly into a global Phase 3 pivotal trial named the NEPTUNE trial. Good news!!!!!

0 · Reply

MallardMike Jul. 8 at 2:15 PM

$OKYO Good news

0 · Reply

Merlintrader Jul. 8 at 12:55 PM

$CRNX $CRNX, $MCRB, $OKYO: Vertex’s $10B Crinetics Deal, Seres’ Microbiome Signal and OKYO’s FDA Phase 3 Pathway https://www.merlintrader.com/biotech-radar-crnx-mcrb-okyo-july-2026/

0 · Reply

prismmarketview Jul. 8 at 12:55 PM

#OkyoPharma (NASDAQ: $OKYO ) says its Type D meeting with the FDA delivered clear alignment on a single‑dose, global Phase 3 NEPTUNE trial of urcosimod in neuropathic corneal pain, opening the door to a potential single‑trial registration pathway in a disease with no approved therapies today. #OKYO #Biotech #Ophthalmology #ClinicalTrials https://prismmarketview.com/companies/okyo-pharma-limited/#news

0 · Reply

MrTicker Jul. 8 at 11:29 AM

$OKYO OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain MT NEWSWIRES 6:28 AM ET 7/8/2026

0 · Reply

TradersLink Jul. 8 at 11:05 AM

$OKYO OKYO gets positive FDA Type D feedback, advances urcosimod into global Phase 3 NEPTUNE trial OKYO said the FDA provided positive Type D meeting feedback that validates its single-dose Phase 3 NEPTUNE design and could allow a single-trial registration pathway, accelerating advancement of urcosimod for neuropathic corneal pain. NEPTUNE is planned as a global pivotal study (~111 patients, 2:1 randomization of 0.05% urcosimod vs placebo) to start in H2 2026 and the company will seek Breakthrough Therapy Designation, though single-trial approval remains conditional on successful results and further FDA review.

0 · Reply

MrTicker Jul. 8 at 11:04 AM

$OKYO OKYO Pharma Announces Positive Feedback From FDA Type D Meeting, Validating Regulatory, Clinical Path Forward For Urcosimod And Supporting Advancement Into Global Phase 3 Pivotal Trial For NCP BENZINGA 6:03 AM ET 7/8/2026

0 · Reply

Orlandotrader Jul. 7 at 8:58 PM

$OKYO wasting Time here Let’s get this Trial started Dempsey!!!

0 · Reply

Zerocool3 Jun. 26 at 4:58 PM

$OKYO Dr. Gary Jacob indeed stepped down as CEO of OKYO Pharma in January 2025. Since then, Dr. Raj Patil has been leading the company's operational business as CEO and President. Although Gary Jacob is still active in the background as a strategic advisor, he no longer holds the executive chair.

2 · Reply

Market Cap	60.02M
Revenue (ttm)	0.00
Net Income (ttm)	-4.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.06

Volume	45,700
Avg Vol	103,732
Day's Range	N/A - N/A
Shares Out	40.56M
Stochastic %K	81%
Beta	0.06
Analysts	Strong Sell
Price Target	$8.33